
|Articles|June 1, 2001
Pioneer in PSA test doubts its predictability
Palo Alto, CA-Urologists have heard more than once from detractors who have said that measuring PSA is not useful as a predictor for prostate cancer. You may now add Thomas A. Stamey, MD-the first investigator to show that the level of serum PSA was proportional to the volume of prostate cancer-to the list of naysayers.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








